Failure of Repeated Cyclophosphamide Pulse Therapy in Childhood Cerebral X-Linked Adrenoleukodystrophy

Abstract

Childhood cerebral X-linked adrenoleukodystrophy (ALD) remains one of the most devastating neurological diseases of childhood. Cardinal features are inflammatory cerebral demyelination that coincides with an advancing zone of gadolinium enhancement on brain MRI. Therapeutic options, including the role of antiinflammatory therapy, are limited and poorly understood. We report the failure of repeated cyclophosphamide pulse therapy to halt the clinical progression or alter the gadolinium accumulation in two cases of childhood cerebral ALD.

Keywords

adrenoleukodystrophy - immunosuppression - cyclophosphamide

• References

• 1 Mosser J, Douar A-M, Sarde C-O , et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361 (6414) 726-730
• 2 Cartier N, Hacein-Bey-Abina S, Bartholomae CC , et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326 (5954) 818-823
• 3 Naidu S, Bresnan MJ, Griffin D, O'Toole S, Moser HW. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol 1988; 45 (8) 846-848
• 4 Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH. Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol 1981; 38 (1) 48-49
• 5 Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51 (6) 630-643
• 6 Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci 1999; 22 (1) 4-12
• 7 Ito M, Blumberg BM, Mock DJ , et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001; 60 (10) 1004-1019
• 8 Tolar JJ, Orchard PJ, Bjoraker KJ, Ziegler RS, Shapiro EG, Charnas L. N-acetyl-L-cysteine improves outcome of advanced cerebral adrenoleukodystrophy. Bone Marrow Transplant 2007; 39 (4) 211-215
• 9 McGuinness MC, Powers JM, Bias WB , et al. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol 1997; 75 (1-2) 174-182
• 10 Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8 (2) 142-154
• 11 Krishnan C, Kaplin AI, Brodsky RA , et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65 (8) 1044-1051
• 12 Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997; 42 (3) 313-318